| Conferences \ BioProcessing, Biologics & Biotherapeutics Congress \ Antibody and Peptide Therapeutics \ Agenda \ Melvyn Little |
| Register | Login |
A Tetravalent Bispecific Antibody (TandAb) for Treating Hodgkin´s Lymphoma – from Gene to ClinicWednesday, 20 July 2011 at 11:45  Add to Calendar ▼2011-07-20 11:45:002011-07-20 12:45:00Europe/LondonA Tetravalent Bispecific Antibody (TandAb) for Treating Hodgkin´s Lymphoma – from Gene to ClinicSELECTBIOenquiries@selectbiosciences.comImmune effector cells are powerful killing agents. To harness them for treating tumors such as Hodgkin´s Lymphoma, we have developed a highly effective bispecific antibody format (TandAb). Product development from the gene to the clinic will be described. |
Add to Calendar ▼2011-07-20 00:00:002011-07-21 00:00:00Europe/LondonAntibody and Peptide TherapeuticsSELECTBIOenquiries@selectbiosciences.com
